Journal
ONCOTARGET
Volume 7, Issue 18, Pages 25862-25871Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.8406
Keywords
HDAC-inhibitor; HDAC1; CIP2A transcription; PP2A; CRC cells
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro, AIRC 5 per Mille
- AIRC-Gruppo Italiano Malattie Mieloprolife-rative [1005]
Ask authors/readers for more resources
This work describes the effectiveness of HDAC-inhibitor (S)-2 towards colorectal cancer (CRC) HCT116 cells in vitro by inducing cell cycle arrest and apoptosis, and in vivo by contrasting tumour growth in mice xenografts. Among the multifaceted drug-induced events described herein, an interesting link has emerged between the oncoprotein histone deacetylase HDAC1 and the oncogenic Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) which is overexpressed in several cancers including CRCs. HDAC1 inhibition by (S)-2 or specific siRNAs downregulates CIP2A transcription in three different CRC cell lines, thus restoring the oncosuppressor phosphatase PP2A activity that is reduced in most cancers. Once re-activated, PP2A dephosphorylates pGSK-3 beta(ser9) which phosphorylates beta-catenin that remains within the cytosol where it undergoes degradation. The decreased amount/activity of beta-catenin transcription factor prompts cell growth arrest by diminishing c-Myc and cyclin D1 expression and abrogating the prosurvival Wnt/beta-catenin signaling pathway. These results are the first evidence that the inhibition of HDAC1 by (S)-2 downregulates CIP2A transcription and unleashes PP2A activity, thus inducing growth arrest and apoptosis in CRC cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available